Humanigen, Inc. is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative, accelerated business models. Lead compounds in the portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML).
Address:
1000 Marina Boulevard
Suite 250
Brisbane, CA 94005
Sector:
Healthcare
Industry:
Biotechnology
NAICS:
Pharmaceutical Preparation Manufacturing (325412)
SIC:
Pharmaceutical Preparations (2834)